Snowflake stock soars on growing enterprise AI demand, AWS partnership


What happened: Snowflake shares (SNOW) jumped 38% pre-market on Thursday after the cloud data company posted better-than-expected quarterly results, driven by accelerating enterprise AI demand for its platform and an expanded deal with Amazon Web Services.

Shares of peer ServiceNow (NOW) also jumped, along with the broader Tech-Software ETF (IGV).

What’s behind the move: Snowflake said AI products contributed to the “strongest sequential product revenue dollar growth” in its history. Fiscal first quarter revenue growth of 33% year over year to $1.39 billion.

The company announced an expanded collaboration with AWS through a new multi-year, $6 billion agreement aimed at accelerating global enterprise AI adoption. It also deepened its partnership with OpenAI.

What else do you need to know: WedBush Securities analyst Dan Ives reiterated an Outperform rating on Snowflake stock while raising his share price target from $270 to $280.

“We continue to believe the software landscape is in the early innings of AI monetization as the disconnect induced by the ‘AI Ghost Trade’ closes for SNOW,” wrote Ives in a client note following the quarterly results.

The broader Software ETF (IGV) has rebounded 24% since mid-April as investors have grown more bullish on companies viewed as direct beneficiaries of artificial intelligence-driven productivity gains. Software firms have been aggressively promoting the integration of generative AI tools into their platforms.

The recent rally marks a sharp reversal from earlier this year when software stocks came under pressure amid fears that artificial intelligence could disrupt traditional software business models.

Ines Ferre is a senior business reporter for Yahoo Finance. Follow her on X at @ines_ferre.

Click here for the latest technology news that will impact the stock market

Read the latest financial and business news from Yahoo Finance

The Snowflake Inc logo, the American cloud computing-based data company that offers cloud-based storage and analytics services, is on their pavilion during the Mobile World Congress 2025 in Barcelona, Spain, on March 5, 2025. (Photo by Joan Cros/NurPhoto via Getty Images)
The Snowflake Inc logo, the American cloud computing-based data company that offers cloud-based storage and analytics services, is on their pavilion during the Mobile World Congress 2025 in Barcelona, Spain, on March 5, 2025. (Photo by Joan Cros/NurPhoto via Getty Images) · NurPhoto via Getty Images





Source link

  • Related Posts

    Snowflake vs. Salesforce earnings: Is AI still disrupting software?

    Snowflake (SNOW) stock is soaring by over 30% on Thursday after the company reported AI demand to have driven better-than-expected first quarter results alongside revenue growth of 33%. PNC Asset…

    CVS Caremark will cover Lilly’s weight loss drug Zepbound again after patient backlash

    CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered medications last year, drugmaker Eli Lilly said Thursday. Subscribe…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Forget LASIK: Safer, cheaper vision correction without lasers or surgery

    Forget LASIK: Safer, cheaper vision correction without lasers or surgery

    Minister Joly to participate in 75th anniversary NATO Summit

    Minister Joly to participate in 75th anniversary NATO Summit

    Snowflake vs. Salesforce earnings: Is AI still disrupting software?

    Snowflake vs. Salesforce earnings: Is AI still disrupting software?

    B.C. premier says Alberta separatism the ‘elephant in the room’ during pivotal moment for Canada

    B.C. premier says Alberta separatism the ‘elephant in the room’ during pivotal moment for Canada

    Some U.S. states stand against AI data centers

    Some U.S. states stand against AI data centers

    CVS Caremark will cover Lilly’s weight loss drug Zepbound again after patient backlash

    CVS Caremark will cover Lilly’s weight loss drug Zepbound again after patient backlash